Clinical Trial

Impact of Omega 3 in Alcohol Use Disorder

Study acronym: W3-AUD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 22, 2023 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to investigate the biological pathways underlying the beneficial effect of omega-3 polyunsaturated fatty acids (n-3 PUFA) on mental health in patients with alcohol use disorder. The main questions this study aims to answer are: * Can n-3 PUFA improve mood disorders (depression, anxiety), craving for alcohol, cognitive impairments and sociability disorders ? * Are the beneficial effects of n-3 PUFAs due to a modification of the gut microbiota and/or the inflammatory status? Participants will : * take a supplementation of omega-3 or placebo during 3 months * do a brain MRI * be interviewed for a dietary anamnesis * provide blood, stool and saliva samples * perform psychological tests and neuropsychological tasks Researchers will compare active comparator (omega-3) with placebo comparator (olive oil) to see if omega-3 can have a beneficial effect on AUD patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-01.
Status change: Not Yet Recruiting → Recruiting 2023-06-20
Trial Details
NCT Number NCT05899660
Lead Sponsor Université Catholique de Louvain
Conditions Alcohol Use Disorder, Severe
Enrollment 100 participants
Start Date 2023-06-19
Primary Completion 2024-12-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-06-22